Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity carcinoma
• Recurrent or persistent disease
• Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest dimension to be recorded) ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
• Must have at least 1 "target lesion" to be used to assess response on this protocol as defined by RECIST criteria
• Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
• Must have had 1 prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound and the initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
• Patients are allowed, but not required to receive, 2 additional cytotoxic regimens for management of recurrent or persistent disease with no more than 1 non-platinum, non-taxane regimen
• Patients who have received only 1 prior cytotoxic regimen (platinum-based regimen for management of primary disease), must meet 1 of the following criteria:
• Platinum-free interval of 9 g/dL
• Creatinine ≤ 1.5 times upper limit normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• CPK normal
• Bilirubin or direct bilirubin normal
• Alkaline phosphatase normal
• Neuropathy (sensory and motor) ≤ grade 1
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection requiring antibiotics (except for uncomplicated UTI)
• No other invasive malignancy within the past 5 years, except nonmelanoma skin cancer
• No known active liver disease or hepatitis
• Willing and able to have a central venous catheter

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from effects of recent surgery, radiotherapy, or chemotherapy
• At least 1 week since prior hormonal therapy directed at the malignant tumor
• Continuation of hormone replacement therapy allowed
• At least 3 weeks since other prior therapy, including biological and immunological therapy directed at the tumor
• Chimeric or human or humanized monoclonal antibodies must be discontinued for at least 6 weeks prior to study entry
• No investigational therapy within the past 30 days
• No prior therapy with docetaxel and/or trabectedin
• No radiation to more than 25% of marrow-bearing areas
• No prior cancer treatment that contraindicates protocol therapy